Spearhead Capital Advisors, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Spearhead Capital Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$120.42 - $169.29 $3,130 - $4,401	-26 Reduced 1.19%	2,151 $314,000
Q1 2022 Apr 28, 2022	SELL	$127.18 - $173.91 $115,097 - $157,388	-905 Reduced 29.36%	2,177 $355,000
Q4 2021 Jan 25, 2022	BUY	$159.56 - $209.29 $26,327 - $34,532	165 Added 5.66%	3,082 $523,000
Q3 2021 Oct 27, 2021	BUY	$169.75 - $207.73 $14,938 - $18,280	88 Added 3.11%	2,917 $551,000
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $51,709 - $71,109	402 Added 16.56%	2,829 $480,000
Q1 2021 Apr 28, 2021	BUY	$126.83 - $175.69 $39,063 - $54,112	308 Added 14.54%	2,427 $343,000
Q4 2020 Feb 02, 2021	BUY	$122.97 - $147.0 $11,805 - $14,112	96 Added 4.75%	2,119 $275,000
Q3 2020 Oct 16, 2020	BUY	$121.19 - $165.49 $14,179 - $19,362	117 Added 6.14%	2,023 $295,000
Q2 2020 Jul 16, 2020	BUY	$104.21 - $156.44 $198,624 - $298,174	1,906 New	1,906 $282,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.